OSI Pharmaceutical Gets a Boost from Cancer Drug - trackseekingalpha

Sign Up | Log In | What is SocialPicks?

OSI Pharmaceutical Gets a Boost from Cancer Drug
Jul 13, 2009 05:34 PM UTC

trackseekingalpha

Return	Risk
-11.17%	HIGH

Tracked Blogger

Profile & Performance

Subscribe to author

Symbol	Sentiment	Start	Return	Closed
DNA	n/a
OSIP	n/a

Via Long Investment Ideas from Seeking Alpha:

By Jon "DRJ" Najarian

OSI Chart Lung Cancer Drug Advances

OSI Pharmaceutical (OSIP) and Roche subsidiary Genentech (DNA) announced that a pivotal Phase III study of Tarceva met a key secondary endpoint of extending overall survival in patients with advanced lung cancer who received the drug immediately after initial chemotherapy. A statistically significant improvement in overall survival was seen in this final analysis of the total patient population. OSIP and Genentech will present during the 13th World Conference on Lung Cancer to be held July 31 to Aug. 4 in San Francisco. OSIP closed at $28.44 Friday but is trading at $30.75 in the pre-market on our Heat Seeker system.

Read the rest of original post »

Add Comment

Be the first to comment on this story and earn 2 points.

Your Comment

IN THE PRESS

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.